Question special
Lead Moderator

To start, I would like to give an opportunity to the authors to elaborate on the significance and impact of their work. What are the greatest clinical implications and future research possibilities based on the findings of this paper? Moreover, how should we begin considerations of the pros and cons of routinely examining all men with metastatic prostate cancer for the presence of germline mutations in DNA-repair genes? Can you see this as standard clinical practice heading into the foreseeable future?